Response of leptomeningeal metastases from breast cancer to hormonal therapy.
Intraventricular chemotherapy with radiotherapy is the standard treatment of leptomeningeal metastasis (LM) from breast cancer; this treatment increases median survival only to about 3 months and is frequently complicated by serious side effects. The authors describe two patients with LM from breast cancer who were treated with hormonal therapy, which provided a neurologic response of at least 12 months and a survival of 14+ and 19 months. Hormonal therapy can be effective and nontoxic for patients with LM from breast cancer.
Boogerd
W
W
Department of Neuro-Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoekhuis, Amsterdam. irene@nki.nl
Dorresteijn
L D
LD
van Der Sande
J J
JJ
de Gast
G C
GC
Bruning
P F
PF
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000556:secondary*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal